NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.
Investigation Details
On November 11, 2024, Neurogene issued a press release reporting "interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome." Although Neurogene characterized the data as "positive", one of two patients given a high dose reported an emerging treatment-related serious adverse event that the Company described as "consistent with known risks of [adeno-associated virus] gene therapy[.]" On this news, Neurogene's stock price fell $31.53 per share, or 44.08%, to close at $40.00 per share on November 12, 2024. Then, on November 18, 2024, Neurogene issued a press release providing an updating, stating that the patient in question "is in critical condition" and that "Neurogene no longer anticipates completing enrollment in the 1E15 vg cohort (low-dose cohort) of NGN-401 in the fourth quarter of 2024". On this news, Neurogene's stock price fell sharply during intraday trading on November 18, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Neurogene securities, you can assist this investigation by visiting the firm's site: bgandg.com/NGNE. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC